Trial Profile
Usefulness of FDG-PET/CT to predict the response after nivolumab in patients with previously treated advanced non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Jul 2018
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 06 Jun 2017 Results (n=24) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 31 May 2016 New trial record